Funding for this research was provided by:
Enterprise Ireland (CFTD/2009/0122, CF/2012/2608)
Horizon 2020 Framework Programme (822258)
Received: 28 November 2019
Accepted: 12 March 2020
First Online: 6 April 2020
Ethics approval and consent to participate
: All animal studies were performed at the facilities of IPS Therapeutique (IPST; Sherbrooke, Quebec, Canada). The institutional animal ethics committee of IPST approved the studies in strict accordance with the guidelines of the Canadian Council on Animal Care and the US NIH Guide for the Care and Use of Laboratory Animals. Human lung tissue was obtained from the Royal Papworth Hospital NHS Foundation Trust Tissue Bank (Cambridge, UK). Written consent was obtained for all tissue samples using Royal Papworth Hospital NHS Foundation Trust Tissue Bank’s ethical approval (East of England - Cambridge East Research Ethics Committee 08/H0304/56 + 5).
: Not applicable.
: EPM, HMR, LB and BTK are employees of ATXA Therapeutics Ltd. BTK is also a member of the board of directors of ATXA Therapeutics Ltd. The authors EPM, HMR, LB and BTK declare that they have no competing interests. AB and DS were employees of IPS Therapeutique Inc. at the time of conducting the work reported in this manuscript. This work was sponsored by ATXA Therapeutics Ltd. The authors AB and DS certify that they have no affiliations with, or involvement in, any organisation or entity with any financial or non-financial interest in the subject matter or materials discussed in this manuscript.